《骨髓增殖性肿瘤课件》由会员分享，可在线阅读，更多相关《骨髓增殖性肿瘤课件（26页珍藏版）》请在金锄头文库上搜索。
1、HongzhiXu Shandong Provincial Hospital,Myeloproliferative Disorders,CONTENTS,Pathogenesis and management of essential thrombocythemia Idiopathic erythrocytosis: a disappearing entity Therapeutic potential of JAK2 inhibitors,Pathogenesis and management of essential thrombocythemia,Pathogenesis,Relati
2、onship of ET to PV and PMF The level of JAK2-STAT5 signaling provides a rheostat that determines whether the disease phenotype is predominantly erythroid or megakaryocytic.,Several lines of evidence suggest a blurring of the distinction between these disorders. A proporation of patients diagnosed wi
3、th ET (see Table 1 for criteria) harbor increased levels of bone marrow reticulin in the absence of other features suggesting a diagnosis of PMF,The variable degree of reticulin accumulation reflects the combined effects of genetic background, disease duration, therapy, clonal burden and the acquisi
4、tion of additional genetic lesions.,Table 1.Suggested diagnostic criteria for essential thrombocythemia(ET),Diagnosis requires A1-A3 OR A1+A3-A5 A1 Sustained platelet count 450X109/L. A2 Presence of an acquired pathogenetic mutation(eg, in JAK2 or MPL). A3 No other myeloid malignancy, especially pol
5、ycythemia vera(PV), primary myelofibrosis(PMF), chronic myeloid leukemia(CML) or myelodysplastic syndrome(MDS). A4 No reactive cause for thrombocytosis and normal iron stores. A5 Bone marrow trephine histology showing increased megakaryocytes with prominent large hyperlobated forms; reticulin is gen
6、erally not increased(2 on a 0-4 scale).,Familial Predisposition to ET and Other Myeloproliferative Neoplasms A relative risk of 7.4 for developing ET in those with an affected first-degree relative.,Are Mutations in JAK2 Disease-initiating Events? The acquisition of a JAK2 mutation was preceded by e
7、ither a deletion of chromosome 20q24 or a mutation in TET2. Direct evidence now exists demonstrating that JAK2 mutations are not the disease-initiating event in some patients, although the frequency of this scenario remains unclear.,Progression to Acute Myeloid Leukemia Progression to acute myeloid
8、leukemia(AML) occurs in a small minority of ET patients and involves the accrual of further genetic events.,Diagnosis and Management Diagnostic Criteria Mutations in JAK2 exon 12 are not thought to occur in patients with ET. The combination of an isolated thrombocytosis with a pathogenetic mutation,
9、 in the absence of iron deficiency or features of PMF, is usually sufficient to make a diagnosis of ET.,Therapy Low-dose aspirin Cytoreductive therapy Hydroxyurea Anagrelide JAK2 inhibitors,Idiopathic erythrocytosis : a disappearing entity,Classification of Erythrocytoses An erythrocytosis can be cl
10、assified depending on the identified cause. The main division is on the basis of primary causes, where an intrinsic defect in the erythroid progenitor cell is associated with an enhanced response to cytokines; or secondary, where the increased red cell production is driven by factors external to the
11、 erythroid compartment, such as increased erythropoietin(EPO) production for any reason. Primary and secondary causes can be classified further as either congenital or acquired(Table2).,Table 2.Causes of an erythrocytosis,Primary Erythrocytosis Secondary erythrocytosis Idiopathic erythrocytosis,Tabl
12、e 2.Causes of an erythrocytosis,Primary Erythrocytosis Congenital Erythropoietin(EPO) receptor mutations Acquired Polycythemia vera (including JAK2 exon 12 mutations),Secondary erythrocytosis Congenital Defects of the oxygen sensing pathway VHL gene mutation (Chuvash erythrocytosis) PHD2 mutations H
13、IF-2a mutations Other congenital defects High oxygen-affinity hemoglobin Bisphosphoglycerate mutase deficiency,Acquired EPO-mediated Central hypoxia Chronic lung disease Right-to-left cardiopulmonary vascular shunts Carbon monoxide poisoning Smokers erythrocytosis Hypoventilation syndromes including
14、 obstru- ctive sleep apnea High-altitude,Local hypoxia Renal artery stenosis End-stage renal disease Hydronephrosis Renal cysts (polycystic kidney disease) Post-renal transplant erythrocytosis,Pathologic EPO production Tumors Cerebellar hemangioblastoma Meningioma Parathyriod carcinoma/adenomas Hepa
15、tocellular carcinoma Renal cell cancer Pheochromocytoma Uterine leiomyomas Drug associated Erythropoietin administration Androgen administration,Investigation of an Erythrocytosis Once an erythrocytosis has been established identification of the cause is the next focus. Clinical Consequences A raise
16、d red cell count will increase the viscosity and thus may have clinical consequences. Management of an Erythrocytosis Reducing the Hct by phlebotomy/venesection reduces the blood viscosity and maybe of benefit. Cytoreductive Low-dose aspirin,Therapeutic potential of JAK2 inhibitors,The V617F mutation is localized in a region outs
